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Highlights 
 AKR1C3 is overexpressed and linked to AR signaling in prostate cancer. 
 Previous work suggests ligands for PPARs are an important target of 
AKR1C3. 
 ShAKR1C3 had no effect on PPARs but enhanced sensitivity to HDAC 
inhibitors. 
 AKR1C3 may regulate the epigenome and is a target alongside HDAC 
inhibition. 
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Abstract 
Background. The aldo-keto reductase 1C3 (AKR1C3) has been heavily implicated in the 
propagation of prostate malignancy. AKR1C3 protein is elevated within prostate cancer 
tissue, it contributes to the formation of androgens and downstream stimulation of the 
androgen receptor (AR). Elevated expression of AKR1C3 is also reported in acute myeloid 
leukemia but the target nuclear receptors have been identified as members of the Peroxisome-
Proliferator Activated Receptor (PPARs) subfamily. Thus, AKR1C3 cancer biology is likely 
to be tissue dependent and hormonally linked to the availability of ligands for both the 
steroidogenic and non-steroidogenic nuclear receptors.  
Methods. In the current study we investigated the potential for AKR1C3 to regulate the 
availability of prostaglandin-derived ligands for PPARg mainly, Prostaglandin J2 (PGJ2).  
Using prostate cancer cell lines with stably reduced AKR1C3 levels we examined the impact 
of AKR1C3 upon proliferation mediated by PPAR ligands.  
Results. These studies revealed knockdown of AKR1C3 had no effect upon the sensitivity of 
androgen receptor independent prostate cancer cells towards PPAR ligands. However, the 
reduction of levels of AKR1C3 was accompanied by a significantly reduced mRNA 
expression of a range of HDACs, transcriptional co-regulators, and increased sensitivity 
towards SAHA, a clinically approved histone deacetylase inhibitor.   
Conclusions. These results suggest a hitherto unidentified link between AKR1C3 levels and 
the epigenetic status in prostate cancer cells. This raises an interesting possibility of a novel 
rational to target AKR1C3, the utilization of AKRIC3 selective inhibitors in combination 
with HDAC inhibition as part of novel epigenetic therapies in androgen deprivation therapy 
recurrent prostate cancer.  
 
Keywords: Prostate cancer, 17B-Hydroxysteroid dehydrogenase, AKR1C3, PPAR, 
prostaglandins, Bezafibrate. 
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Introduction 
Nuclear Receptors (NRs) regulate multiple gene targets controlling cell growth and differentiation 
in many self-renewing tissues including hematopoietic and epithelial cells. The ability of NRs to 
exert these gene regulatory effects is dictated by the supply of ligand availability and epigenetic 
context (reviewed in1,2).  
Prostate cancer (CaP) represents an attractive disease with which to target NR signaling in either 
chemoprevention or chemotherapeutic strategies. Early stage disease is a potential target for 
chemotherapies that target NRs such as VDR, RARs/RXRs and PPARs3-5. Expression of these 
receptors is sustained in early stage CaP and they are well established as exerting a range of tumor 
repressive effects. For example, PPARg receptor activation induces anti-proliferative, pro-
differentiating gene targets and has subsequently been the target of various clinical trials 
including a phase II clinical study with Troglitazone6. At late stage CaP targeting of the AR by 
androgen deprivation therapy (ADT) forms the current treatment mainstay for advanced prostate 
cancer. However, in ADT-R CaP (androgen deprivation therapy - recurrent prostate cancer), is 
predominantly lethal with limited alternative therapeutic strategies7.  
In late stage and ADT-R CaP aberrant co-repressor actions preclude NR activation, impairing   
anti-proliferative capacity and further epigenetic mechanisms contribute to this resistance8 with 
similar events disrupting AR signaling9,10 (reviewed in11). Specifically, PPARg actions are 
epigenetically disrupted and can be targeted selectively by using HDAC inhibitor co-
treatments12,13. Elevated levels of the co-repressors NCOR1, and to a lesser extent 
NCOR2/SMRT, correlated with, and functionally drive, the selective insensitivity of PPARa/g 
receptors towards dietary derived and therapeutic ligands13,14. 
One approach to target NR signaling in CaP is to target the enzymes that regulate ligand 
availability. Aldoketoreductase 1C3 (AKR1C3) is a multifunctional enzyme and acts as a type 2 
3-alpha-Hydroxysteroid dehydrogenase or 17-beta-HSD type 5. A key regulator of steroidal 
metabolism, it is implicated in cancer progression. For example, silencing of AKR1C3 has been 
shown to inhibit cervical cancer metastasis15. In CaP, AKR1C3 actions are implicated in the 
generation of androgens16-19, AR activation and has been investigated as a potential biomarker for 
CaP progression20,21. However, AKR1C3 is able to convert various different substrates and 
reflecting this, it has been implicated in the altered metabolism of chemotherapeutics propagating 
cancer cells resistance22. Perhaps reflecting this promiscuity over substrate choice, AKR1C3 is 
often overexpressed in prostate cancer tissues and prostate cancer cell lines23. Furthermore its 
expression is elevated in cell lines with either absent or low levels of AR24 suggesting that 
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substrates may include those independent of androgen signaling; and 5α-Dihydrotestosterone may 
not be the only product of AKR1C3 25,26.   
Previous publications have considered the regulatory actions of AKR1C3 on alternative 
substrates, including the arachidonate-derived prostaglandins that act as de novo ligands for 
PPARg27 . The expression level of AKR1C3 has been examined in ADT-R CaP tissue and cells 
lines, including PC-3 and DU 145 cells, and been shown to be elevated compared to less 
aggressive counterparts and directly proportional to the 11b-PGF2 levels 
28. We and others have 
examined the ability of AKR1C3 to convert prostaglandin D2 (PGD2), into 9-alpha, 11beta-
prostaglandin F2 
28,29 (a ligand for the FP receptor, which is a driver of cell proliferation) 
preventing the alternative spontaneous and non-enzymatic generation of the potent PPARg ligand 
PGJ2 
30,31. Additionally, the PPARg mediated protective action of AKR1C3 have been 
investigated by exploiting 6-Medroxyprogesterone acetate (MPA) an inhibitor of AKR1C3 32. In 
leukemic systems a synergistic effect on cell death occurs with the combination of MPA with 
PPARg ligand bezafibrate 33. Combinatorial treatments of MPA and PGD2 have corroborated this 
in other cancer models to induce apoptosis and cell cycle arrest through PPARg driven activation 
pathways 34, and other studies have echoed this approach in CaP 35.  
Therefore, the current study, examined the possibility that an AR-independent mechanism for 
AKR1C3 was operating in CaP cells and, in particular, we focused on a potential role in ADT-R 
CaP cells where AR signaling is either diminished or lost. By generating CaP cell lines stably 
expressing a short hairpin siRNA sequence to AKR1C3 we investigated responses to treatment 
with the PPARg ligand precursor and AKR1C3 substrate PGD2.  
 
Materials & Methods 
Ligands. Suberoylanilide hydroxamic acid (SAHA) (Merck Inc, New Jersey, USA), GW9662  
(Sigma-Aldrich) and Prostaglandin D2 (Sigma-Aldrich) were stored in DMSO (Sigma-Aldrich) as 
100mM stocks. Bezafibrate (PPARa/g), 6-medroxyprogesterone acetate (Sigma-Aldrich), and 
Indomethacin (Sigma-Aldrich) were stored as 10mM stocks in DMSO.   
Cell Culture and shRNA Knockdown. ShRNA targeting AKR1C3 oligonucleotides containing 
the short hairpin sequence (Sigma-Aldrich) were annealed and inserted in a pcDNA3.1 vector 
(Invitrogen). Stably transfected cells were exposed to 100mg/ml Neomycin sulphate (Sigma-
Aldrich) as a selection agent. Human prostate cell lines used RWPE-1, LNCaP, PC-3, DU 145 
were purchased from American Type Cell Culture (ATCC) Manassas, Virginia USA. RWPE-1 
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cells were maintained within Keratinocyte serum free medium (K-SFM) (Invitrogen GIBCO) 
used in combination with the recommended supplements of bovine pituitary extract (0.05mg/ml) 
(BPE) and human recombinant epidermal growth factor (5ng/ml) (EGF). LNCaP, PC-3 and DU 
145 cells were maintained in RPMI 1640 medium (Sigma-Aldrich) containing 10% fetal bovine 
serum (Invitrogen), 2mM L-Glutamine and containing 100 units/ml Penicillin and 100μg/ml 
Streptomycin. Cells were kept at 37oC in 95% air and 5% CO2. Cells were washed in sterile 
phosphate buffered saline (PBS) and split using Trypsin-EDTA (Sigma-Aldrich) and seeded into 
new flasks containing fresh media. All experiments were conducted using cells between passages 
15 and 28.  
Primary prostate tumor material. All tumors were collected under IRB approval at Roswell 
Park Cancer Institute (RPCI), specifically the Genitourinary Disease Site Research Network at 
RPCI, which assesses applications for non-human subject research under guidance of the Office 
of Research Subject Protection. All patients at RPCI give written consent to allow tumor material 
not needed for pathological grading to be considered for non-human subject research. Total 
mRNA from local tumors and adjacent non-neoplastic tissue from the same patient were extracted 
from snap frozen radical prostatectomy samples with subsequent frozen section analysis for 
quality control. The frozen section H&E was evaluated by a board certified pathologist for 
prostatic adenocarcinoma versus benign tissue. Segments of tissue corresponding to prostatic 
adenocarcinoma with equal to or greater than 70% neoplastic nuclei are submitted for RNA 
isolation. RNA processing was done in the Pathology Resource Network facilities with standard 
operating procedures as described previously 36.  
Proliferation assays. Proliferation (ViaLight HS, LumiTech, Nottingham, U.K.) was measured 
as described previously 37 and optimized using different seeding densities to ensure exponential 
proliferation through the course of the experiment. Cancer cell lines (2x103 cells/well) and 
RWPE-1 (4x103 cells/well) were plated in 96-well, white-walled plates (Fisher Scientific Ltd., 
Loughborough, U.K.), dosed with agents to final volume of 100µl/well and incubated for 
96hours, with re-dosing after 48hours. Cells were normalized to vehicle control treated wells 
performed in each separate assay plate. Each treatment was performed in technical triplicate and 
in biological triplicate experiments.  
Q-RT-PCR. cDNA was prepared using random primers (Promega) and target genes relative 
expression quantitated using ABI 7500 - Applied Biosystems. Sequences for  
AKR1C3 FORWARD GGGATCTCAACGAGACAAACG REVERSE 
AAAGGACTGGGTCCTCCAAGA PROBE TGGACCCGAACTCCCCCGGTG were designed 
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and validated. 18S VIC-labeled probe was used as an endogenous control (Applied Biosystems). 
Measurements were carried in triplicate, in triplicate wells for each condition and ddCt fold 
changes calculated. 
Multi-target micro-fluidic Q-RT-PCRM. Measurement of targeted multiple gene transcripts was 
undertaken on custom-designed TaqMan Low Density Array (ABI 7900HT Fast Real-Time PCR 
System) as described previously 14 the full 95 gene list is available upon request. Briefly, the array 
included probes and primers for 18S and the gene targets in nine functional groups whose 
expression together reflects nuclear receptor signaling capacity. These were 1. Nuclear receptors 
(e.g. high and broad affinity such as VDR and PPARs); 2. Nuclear receptor co-factors (e.g. co-
activators [p160 family, non-p160 members, members of the ‘bridging’ DRIP/TRAP complex], 
co-repressors [NCOR1, NCOR2/SMRT, COPS2/TRIP15/Alien]; 3. Histone modifiers (histone 
deacetylases [e.g. HDACs hSIRT1] and acetyltransferases [P300, CBP, PCAF], histone 
methyltransferases [SUV39H1, SUV39H2], demethylases [KDM1A/LSD1], Histone deaminases 
[e.g. PAD14]); 4. Metabolic enzymes (e.g. CYP24 and SULTA1); 5. Cell death regulators (e.g. 
CASP4 and BAX); 6. Transcription factors (e.g. YY1 and ID1); 7. Cell surface transporters (e.g. 
ABC transporters such as MRP3); 8. Cell cycle regulators (e.g. CCND1, GADD45a, CDKN1A, 
TP53); 9. Signal transduction (e.g. IGFBPs, MAPKs, CDH1). The exact choices represented in 
classes 1-3 were guided by SAGE expression data from normal prostate tissue 38 and those in 
classes 4-9 included known direct target genes for nuclear receptors 39-46. Total mRNA from cell-
cycle sorted cells was quantified in triplicate samples measured in duplicate as described 
previously 14.  
Fold changes were calculated for target gene expression and statistical analyses carried out using 
the TIGR MultiExperiment Viewer 4.0, MeV. A one sample t-test analysis based on permutation 
(Westfall Young stepdown 47 – MaxT correction) was used to identify genes significantly 
expressed. In this case vectors containing gene expression values were tested against the mean of 
18S fold changes. One-Way ANOVA was used to identify genes that were differentially 
expressed for the shAKR1C3 PC-3 knock-down experiment compared to vector only PC-3 
controls.  
Western immunoblotting Total proteins were electrophoresed in a 12.5% gel, for 90 minutes at 
120 volts. Proteins were then transferred onto PVDF (Polyvinylidene fluoride) membrane (45 
minutes at 80 volts). The PVDF membranes were then left in 5% non-fat milk diluted in Tri-
buffered saline containing 2% Tween (TBS-T) detergent for 45 minutes. Monoclonal anti-
AKR1C3 antibody (Sigma-Aldrich) produced in mouse was diluted 1 in 10,000 into 5% non-fat 
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milk diluted in TBS-T. The PVDF membranes were left in the primary antibody mixture overnight 
in a cold room (5oC) to prevent evaporation. The PVDF membranes were washed in TBS-T for 15 
minutes changing the TBS-T every 5 minutes. Secondary HRP-labeled anti-mouse 
immunoglobulin was diluted 1 in 10,000 into TBS-T and the membranes incubated in the mixture 
for 45 minutes. Chemoluminescent ECL western blotting detection kit (Amersham, GE Health 
Care) was added in accordance with manufacturer’s protocol.    
Statistical analysis. Data shown are mean ± SEM of at least three independent experiments with 
statistical significance defined as P <0.05  (*P < 0.05; **P < 0.01; ***P < 0.001) using unpaired 
Students T-test and were conducted with Prism (GraphPad, CA). Statistical analysis on real-time 
PCR data was performed on mean dct values. 
 
Results 
AKR1C3 expression is elevated in prostate cancer cell lines and primary prostate cancer 
material. Figure 1A illustrates Q-RT-PCR data for AKR1C3 in CaP cell lines, normalized to 
RWPE-1 non-malignant prostate cells. Significant elevation of AKR1C3 was demonstrated in 
PC-3 and LNCaP cancer cell lines (p <0.05); LNCaP (5.08 ± 1.0 SEM), PC-3 (7.54 ± 0.1 
SEM). Figure 1B shows expression of AKR1C3, PPARA and PPARG in thirteen human 
primary tumors compared to matched normal tissue, derived from radical prostatectomy. 
There was a significant increase in AKR1C3 levels (2.69 ± 1.7 SEM). PPARA and PPARG 
levels were comparable between normal and tumor samples 48.   
Neither AKR1C3 inhibition nor knockdown enhances PPAR anti-proliferative 
signaling. Previously, studies of acute myeloid leukemia have shown combinatorial anti-
tumor activity when AKR1C3 inhibitors are combined with Bezafibrate (a dual PPARa/g 
ligand). Assuming prostate cell lines have comparable basal turnover of cholesterol-derived 
prostaglandin substrate the similar response would be observed. However, the use of 
AKR1C3 inhibitors either indomethacin or 6-medroxyprogesterone acetate 49 did not enhance 
the anti-proliferative effects of Bezafibrate against the non-malignant RWPE-1 cells or either 
CaP cell line (Figure 2A).  
Stable transfection of short hairpin RNA targeted towards AKR1C3 in PC-3 and DU 145 
resulted in significant reduction in both AKR1C3 mRNA (Figure 2B) and protein levels 
(Figure 2C). Cells were then treated with the PPARg agonist precursor PGD2 to examine the 
biological impact of AKR1C3 reduction. Figure 2D demonstrates reduction of AKR1C3 
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levels had no significant affect on proliferative response to PGD2 within PC-3 (Vector Only 
(VO) and shAKR1C3) and DU 145 (VO and shAKR1C3) cells. These data suggest that 
shAKR1C3 PC-3 and DU 145 cells have unchanged response to the PPARg ligand precursor 
PGD2.  
Cell proliferation in response to SAHA in shAKR1C3 transfected cells.  Explanations for 
deficiency of AKR1C3 inhibitor impact may involve FP1 receptor expression and inherent 
variations in export/import of prostaglandins. However, we reasoned that the lack of a 
response to AKR1C3 inhibitors maybe due to epigenetic blockade of PPARg transcriptional 
actions. Therefore, the HDAC inhibitor acid SAHA was used to treat AKR1C3 knockdown 
cells in an attempt to overcome epigenetic resistance at PPARg targets. Down regulation of 
AKR1C3 in DU 145 cells resulted in significant sensitization to the anti-proliferative actions 
of SAHA. (Figure 3 A and B). A similar trend was observed in PC-3 ShAKR1C3 cells 
although this did not reach significance when compared SAHA treated PC-3 VO cells 
(Figure 3 A and B).  The lesser difference in PC-3 cells may relate the to greater sensitivity 
of PC-3 VO to SAHA treatment alone when compared to DU 145 VO cells which displayed 
no antiproliferative response to SAHA. However, SAHA treatment did not sensitize 
shAKR1C3 cells to either the PPARg ligand precursor PGD2 or the direct PPARg ligand 
GW9662. Interestingly, DU 145 cells revealed a significantly increased sensitivity to PGD2 
in shAKR1C3 cells. This reflects data on chemical inhibition of AKR1C3 by MPA leading to 
increased sensitivity to Bezafibrate (Figure 2A).  
Multi-targeted micro-fluidic QT-RT-PCR of the NR network. The above findings in two 
prostate cancer cell line models suggest that the role of AKR1C3 in CaP is different from that 
in leukemia and is only weakly linked to the protection of PPARg. To reveal the impact of 
reduced AKR1C3 levels in this priming event we examined expression of the NR network 
using a previously established microfluidic PCR approach8,14. We selected PC-3 cells for 
these experiments as arguably it arguably is a more relevant model of ADT-RCaP than DU 
145 cells, as it in vivo it will metastasize to the same sites as observed in human disease50. 
The most significantly deregulated genes in shAKR1C3 compared to VO PC-3 cells are 
shown in Figure 4. Interestingly, a common downregulation of a range of epigenetic 
regulators was observed, alongside AKR1C3 downregulation. These include HDACs, NR co-
activators and NRs and PPARg coactivator (PPARGC1A). In addition the histone 
methyltransferase SET7 and proto-oncogene MYB were significantly down-regulated in 
shAKR1C3. The NFkB complex component IKBkB was the only gene to be significantly 
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upregulated in the presence of shAKR1C3. Transcriptional activators forming the NFkB 
complex have been found to be important in prostate cancer progression and human prostate 
cancer prognosis 51-53. This increase of NFKB in response to shAKR1C3 is of particular 
interest as it is a key driver of prostate cell proliferation and AKR1C3 presence influencing 
NFkB activity (through PGF2 production) has also been suggested by others 
54. 
 
Discussion 
The current study was undertaken to investigate the roles of AKR1C3 in CaP, as this enzyme 
is increasingly a focus in CaP research that includes its altered expression and function. The 
studies of others have focused on the role of this enzyme to alter ligand availability for 
steroidogenic androgen and estrogen receptors in the prostate. Additionally, studies and have 
considered the impact of PGD2 on cell proliferation in cells that over-express AKR1C3 
55-59. 
By contrast, our previous studies show elevated AKR1C3 deprives AML cells of J-series 
prostaglandins that can act as endogenous PPAR ligands. Given that PPARg ligands have 
been investigated for the treatment of various cancer types for example neuroblastomas 60, 
colorectal 61, breast and prostate cancers 62,63. It was hypothesized that the role in CaP for 
AKR1C3 may be to silence PPAR signaling. Furthermore, it has been demonstrated that 
stable expression of AKR1C3 in hormone dependent MCF-7 breast cancer cell lines 
negatively impacts anti-proliferative actions of PGD2 
27.  
This study investigated AKR1C3 function by undertaking knock-down and chemical 
inhibition approaches in parallel to compare findings to previously published over-expression 
approaches 56,57.  In particular an overexpression investigation of AKR1C3 in PC-3 cells 
found overexpression promotes proliferation 35. However, this study found PGD2 exposure to 
overexpressing AKR1C2 and AKR1C3 PC-3 models significantly reduces proliferation 
compared to controls.  However, in this study reduction of AKR1C3 in the presence of PGD2 
had no impact upon proliferation. This disparity reflects the unclear interplay between 
AKR1C2, AKR1C3 in prostaglandin metabolism.  
PC-3 and DU 145 cells are derived from ADT-R CaP cells that are insensitive to AR 
signaling but retain the capacity for PPAR signaling. Therefore, knockdown of AKR1C3 in 
these models allows a clearer examination of the role of AKR1C3 in regulating PPARg. 
However, shAKR1C3 expression did not significantly alter responses to either endogenous 
(PGD2) or synthetic PPARg (GW9662) ligands.  
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These data support the concept that either AKR1C3 is not a major regulator of PPARg in 
prostate cells or that in CaP the ability of AKR1C3 to exert such an action is overridden by 
epigenetic events36,37,64. Therefore SAHA was utilized in an attempt to restore PPARg 
function. Interestingly, the shAKR1C3 clones of DU 145 were significantly more sensitive to 
SAHA than controls; in PC-3 cells this was smaller and non-significant but trending in the 
same direction. This supports a hitherto unsuspected link between AKR1C3 actions and the 
epigenome. The anti-proliferative effects of combining AKR1C3 knockdown and SAHA 
treatment were not further enhanced in the presence of PGD2, reinforcing the notion that 
these epigenetic actions of AKR1C3 in CaP cells are independent of PPARs. It is however, 
possible alternative routes of 15delta-PGJ2 elimination in particular, conjugation and 
dismissal by glutathione could play a contributory role in the absence of PGD2 response.  
The fact that reduction of AKR1C3 levels lead to increased sensitivity towards SAHA 
suggested that AKR1C3 has a role in promoting CaP survival, proliferation and its removal 
whilst not directly affecting cell growth primes cells for sensitivity to other potential CaP 
therapeutics. This suggests overexpression of AKR1C3 has an impact upon the epigenetic 
state of the cell, and is independent of both PPAR and AR signaling, (given the 
diminished/absent AR state of these cells). The down regulation of a number of HDACs 
following AKR1C3 knockdown supports the hypothesis that AKR1C3 in some manner is 
able to regulate enzymes governing epigenetic gene regulation, explaining why the cells gain 
sensitivity to SAHA. Interestingly, the upregulation of IKBkB correlates with previous 
findings suggesting a link between AKR1C3 and NFkB signaling pathways 65,66. More 
broadly to establish the association of AKR1C3 with tumor status The Cancer Genome Atlas 
(TCGA) data was examined to identify genes associated with AKR1C3 signalling, and in 
parallel the AR and PPARg signalling. The goal was to reveal commonly distorted 
components and to infer how AKR1C3 may be co-expressed with either of these pathways, 
and at what stage of prostate cancer. We mined RNA-Seq associated with AKR1C3 in two 
different cohorts of prostate cancer samples in TCGA, namely, the University of Michigan 
cohort of 94 advanced stage and invasive tumors 67 and the Stand Up to Cancer (SU2C) 
cohort of 118 metastatic castrate recurrent tumors 68. From these analyses we generated 
heatmaps for each of the tumor cohort (Supplementary Figure 1). In each case AKR1C3 (red 
arrowhead) grouped by expression in a different cluster than the AR (Black arrowhead). In 
particular AKR1C3 expression clusters more closely with PPARs than the AR. These 
findings suggest that taking an unbiased approach to the networks in which AKR1C3 is 
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implicated supports a role of close association with PPARs rather than the AR and this is 
especially evident in aggressive and advanced disease that has failed anti-androgen treatment.  
Furthermore in the SU2C cohort of 114 tumors, AKR1C3 is over-expressed and amplified in 
4% of tumors. However network analyses69 of AKR1C3 reveals a direct protein-protein 
interaction with ZHX1 which is a corepressor and known to recruit HDACs70. ZHX171 is a 
relatively unexplored protein.  Large-scale protein-protein screens reveal that it interacts with 
proteins including histone deacetylase (HDAC1), the DNA methyltransferases (DNMT1 and 
DNMT3B)72, and a number of transcription factors (NFYa and b) 73. These findings generate 
confidence that a ZHX1 complex initiates chromatin condensation and leads to gene 
silencing. Together we believe strongly that our data generated by two different experimental 
approaches, and these parallel findings from others indicate a direct and functional link 
between AKR1C3 and the regulation of the epigenome. 
The current study has revealed a novel role of AKR1C3 expression on the epigenetic status of 
prostate cancer cells that is independent of AR and PPARs signaling and highlights the 
potential for selective inhibitors of AKRIC3 in combination with SAHA or other HDAC 
inhibitors as prospective therapy in AR resistant disease (Figure 5). 
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Figure captions 
 
Figure 1. (A) AKR1C3 is elevated in most but not all prostate cancer cell lines and tissue 
samples. Total RNA from RWPE-1, LNCaP, PC-3 and DU 145 cells was extracted and 
reverse transcribed. Levels of AKR1C3 mRNA were measured using Q-RT-PCR using 
ribosomal 18S as an endogenous control. Values were normalized relative to the non-
malignant immortalized prostate RWPE-1 cell line shown as fold change in AKR1C3. Bars 
indicate mean values ± SEM of at least three independent biological measurements 
performed in triplicate PCR wells. (B) AKR1C3 is elevated in most human prostate 
cancer tissue samples. Thirteen samples of human prostate tumors were used and total 
mRNA extracted and subject to reverse transcription. The Q-RT-PCR was performed on the 
resulting cDNA using 18S as an endogenous control. The ddCt values for non-tumorigenic 
tissue samples were normalized and compared to human tumor samples. Statistical analysis 
was performed using t-test. *=p-value 0.05, **=p-value 0.01, ***=p-value 0.001. 
 
Figure 2. Reducing AKR1C3 levels is unable to restore anti-proliferative PGD2 
response. (A) RWPE-1, PC-3 and DU 145 cells were plated out at 2x103 cells per well with 
bezafibrate (0.1M) alone or in combination with indomethacin (20M) or MPA (0.5M). 
After incubation for 48 hours the cells were re-dosed again. Total treatment time was 96 
hours. Bars indicate the mean of at least three independent experiments ±SEM. (B) PC-3 and 
DU 145 shAKR1C3 cells show significant reduction in AKR1C3 mRNA and protein in 
comparison to vector only. Q-RT-PCR was performed on the resulting cDNA using 18S as an 
endogenous control. (C) DU 145 shows Western immunobloting analysis of shAKR1C3 
transfected cells and vector only cells probed with AKR1C3 specific antibody and detected 
using chemoluminesence. Image shown is representative of three independent experiments.  
(D) Cells were plated out at 2x103 cells per well with PGD2 added (0.62M, 1.25M, 2.5M, 
or 5.0M) and after incubation for 48 hours the cells were re-dosed with PGD2.  Total 
treatment time was 96 hours.  Each data point represents the mean of four experiments each 
in triplicate wells ± SEM. Statistical analysis was performed using t-test *=p-value 0.05, 
**=p-value 0.01, ***=p-value 0.001. 
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Figure 3. The HDAC inhibitor SAHA shows no interaction with PPARg mediated 
signaling. (A) PC-3 and DU 145 cells were plated out at 2x103 cells per well with PGD2 
(2.5M) alone or in combination with SAHA (0.5M). After incubation for 48 hours the cells 
were re-dosed again. Total treatment time was 96 hours. Bars indicate the mean of at least 
three independent experiments ±SEM. Statistical analysis was performed using t-test *=p-
value 0.05, **=p-value 0.01, ***=p-value 0.001. (B) PC-3 and DU 145 cells were plated out 
at 2x103 cells per well with GW9662 (1.0M) alone or in combination with SAHA (0.5M), 
after incubation for 48 hours the cells were re-dosed again. Total treatment time was 96 
hours. Bars indicate the mean of at least three independent experiments ±SEM. Statistical 
analysis was performed using t-test *=p-value 0.05, **=p-value 0.01, ***=p-value 0.001. 
Figure 4. AKR1C3 knockdown influences a network of genes involved in transcriptional 
regulation. Basal PC-3 vector only controls and shAKR1C3 PC-3 samples were used. Total 
mRNA was collected and added to a micro-fluidic reverse transcription Q-RT-PCR two step 
reaction. Primer sets on the card were selected for their nuclear receptor prostate specific 
context consisting of nine groups listed in the materials and methods section. 
Figure 5. A model of AKR1C3 mediated epigenetic resistance in prostate cancer. (a) 
PGD2 is responsible for the generation of PPARg ligand PGJ2. (b) Increased AKR1C3 levels 
divert PGD2 converting it to 11b-PGF2 contributing to the activation of proliferative 
transcription factors such as the NFkB complex. (c) Observations in shAKR1C3 prostate 
cancer cells suggest AKR1C3 plays a role in sustained repression of anti-proliferative genes, 
this can be relieved with impairment of AKR1C3 activity combined with the treatment of 
HDAC inhibitor permitting access to the HATs responsible for permissive gene activation. 





